Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Why Do Active Funds Underperform Benchmark? This overview breaks down fees, manager skill, and market efficiency to explain gaps in performance and how to navigate them.
22,204 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Timing matters for Required Minimum Distributions. Learn practical strategies to decide when to take your RMDs, how t...
Evolution Petroleum Corp reaches a historic 50th consecutive quarterly dividend, delivering a 10.6% yield at a $4.50 ...
With $1,000 in hand, your goal is steady income and growing wealth. This guide shows how to identify the ultimate div...
A conflict over Iran threatens Asia's access to fertilizer and helium, risking farm yields and semiconductor supply c...
Geopolitical tensions between the U.S. and Iran are dominating crypto moves, with Bitcoin and XRP trading in tight ra...
IonQ faces a pivotal year as government and enterprise demand grows for quantum hardware and software. Analysts outli...
UBS boosts its price target on Xcel Energy to $89 while maintaining a Buy rating, saying the stock could year-end hig...
MaxCyte's 2025 earnings journey hinges on platform momentum, partnerships, and cash discipline. This guide breaks dow...
Women are breaking into top-paying, traditionally male-dominated fields. In 2026, surgeons, airline pilots, and softw...
A 5% pullback in the Nasdaq in 2026 echoes big past moves and offers clues about which stocks tend to fare best durin...
Gold prices fell as headlines about US-Iran tensions eased, while Bitcoin and other risk assets climbed, signaling a ...